The Profit-Driven Paradox: How Private Equity Turned Autism Therapy into a $7 Billion Medicaid Goldmine
In the high-stakes world of modern healthcare finance, a troubling trend has emerged at the intersection of disability advocacy and corporate acquisition. An extensive six-year investigation by The 74 has revealed that while federal officials and political pundits argue over the origins of autism therapy fraud, a massive, systemic redirection of taxpayer funds has occurred. Between 2019 and 2024, private equity firms—entities designed for rapid profit extraction—injected themselves into the Applied Behavior Analysis (ABA) industry, capitalizing on a $7 billion stream of Medicaid payments while frequently sidelining the well-being of the children they claim to treat.
The investigation, which analyzed a massive dataset of 275 million billing records, exposes a landscape where the pursuit of "cures" has been commodified into a lucrative, often harmful, behavior-modification pipeline. As political figures like Elon Musk and the Department of Government Efficiency (DOGE) focus on the optics of fraud, the underlying structural rot—a fusion of predatory investment and loosely regulated therapeutic standards—continues to expand, often at the expense of the very children Medicaid is intended to protect.
The Architecture of the Industry: A Chronology of Expansion
The transformation of autism therapy into a massive industry did not happen in a vacuum. It was the result of a decades-long push for insurance mandates that, while born from the genuine desperation of parents seeking help for their children, inadvertently created a regulatory vacuum.
- 1960s–1980s: Psychologist Ole Ivar Lovaas develops the "Lovaas Method," a precursor to modern ABA that utilized a rigid system of rewards and punishments. Historically, this method shares a troubling lineage with the development of LGBTQ conversion therapy.
- 2005–2007: Lorri Unumb, a mother of an autistic son, spearheads the push for "Ryan’s Law" in South Carolina, the first mandate requiring insurers to cover ABA. Her success provides the blueprint for a nationwide lobbying campaign.
- 2014: The Obama administration clarifies that the Affordable Care Act requires publicly subsidized health plans, including Medicaid, to cover autism treatment. This policy shift effectively opens the floodgates for billions in federal funding.
- 2015–2024: Private equity firms recognize the stability of Medicaid-backed revenue and begin a wave of aggressive consolidation. According to data from the Brown University School of Public Health, 574 sites were acquired by private equity during this period.
- 2019–2024: The 74’s analysis of Medicaid claims shows a 381% surge in the six most common ABA billing codes, with private equity-backed firms dominating the market.
- 2022–2025: A series of federal audits reveals widespread improper billing and "potentially inappropriate" claims across both red and blue states, sparking a national conversation about oversight.
Supporting Data: The Cost of Compliance
The financial scale of this industry is staggering. During the six-year window analyzed, Medicaid billing for ABA therapy reached nearly $7 billion. To put this into perspective, this figure exceeds the amount spent over the last 20 years on research and programs under the Autism CARES Act—the primary federal mechanism intended to improve the quality of life for autistic individuals.
The investigation highlights a "purple problem": audits in states like Colorado, Indiana, Wisconsin, and Maine have all flagged millions in improper payments. In Colorado alone, Medicaid spending on ABA ballooned from $60 million in 2019 to $163.5 million in 2023. Auditors found that in nearly every case examined, records were riddled with "copy-paste" notes, billings for unallowable activities like naps, and a complete lack of individualized treatment plans—a requirement for the therapy’s effectiveness.
Furthermore, the concentration of private equity-owned centers directly correlates with states that have the most generous insurance benefits. In states like California and Texas, the density of these facilities is highest, creating a feedback loop where firms extract maximum revenue by encouraging the most intensive (and expensive) level of care: 40 hours a week of therapy, regardless of the child’s age or actual clinical needs.

The Human Cost: Therapy Over Education
Perhaps the most harrowing aspect of this investigation is the encroachment of therapy on the right to public education. Federal auditors discovered instances where school-aged children were kept in standalone ABA centers full-time for years, effectively denying them access to the classroom.
One Colorado child, referred to ABA at age 2 in 2009, remained in the system until age 16. Over the final six years of that stint, Medicaid paid over $500,000 for a treatment plan that lacked any independent evaluation of its continued necessity. Similarly, an Indiana child was kept in 35-hour-a-week therapy until age 11, with centers citing a standardized statement that the family had "taken responsibility" for education—a loophole that allowed the facility to continue collecting lucrative Medicaid reimbursements.
Experts like Ari Ne’Eman, former director of the Autistic Self-Advocacy Network, argue that this model is inherently flawed. "Forty hours a week of therapy is a full-time job for a 3-year-old," Ne’Eman notes. "It’s harmful for kids and families first and foremost, but I also think it’s a poor use of public funds."
Official Responses and Corporate Defenses
The firms at the center of these acquisitions maintain that their involvement is a force for good. Blackstone, which acquired the Center for Autism and Related Disorders (CARD) in 2018, characterized the subsequent bankruptcy and closure of hundreds of centers as a result of a "perfect storm" of COVID-19 and labor shortages. They contend they were never involved in "specific clinical treatment decisions."
Similarly, Centria Healthcare, the largest Medicaid biller in the dataset, has repeatedly defended its practices despite multiple state-level investigations and lawsuits regarding billing and care quality. CEO David Harbour maintains that the company’s work is "grounded in a commitment to ethical care."
However, industry critics point out that the private equity structure is specifically designed to shield parent companies from liability. When a portfolio company is caught in fraud or faces bankruptcy, the investment managers simply move on, leaving the debt and the consequences of poor care with the local entity. As Professor Rosemary Batt of Cornell University puts it, "If a company gets caught in fraud, it’s just the cost of doing business."

The Implications: A Future at Risk
The current political climate threatens to exacerbate these issues rather than solve them. With the incoming Trump administration and figures like Robert F. Kennedy Jr. questioning established medical research, there is a palpable fear among disability advocates that the modest progress made in understanding autism could be reversed. The recent withholding of Medicaid funds from states like California and Minnesota—framed as a crackdown on "woke ideology" and fraud—has already resulted in the loss of services for many vulnerable individuals.
The legal landscape is shifting as well, but often in ways that favor the industry. Colorado’s recent legislation, intended to "curb abuses," has been criticized by the disability community for creating a licensing board dominated by the very therapists whose industry is under fire. By failing to include independent mental health professionals or autistic adults with lived experience, the new laws risk enshrining the existing ABA model rather than reforming it.
As the industry continues to consolidate, the fundamental question remains: Who is this system serving? When therapy centers prioritize 40-hour-a-week billing cycles over the developmental needs of children, and when private equity firms extract billions in taxpayer funds while providing questionable clinical outcomes, the system ceases to be a healthcare model and becomes a financial instrument.
For thousands of families, the "gold standard" of ABA is beginning to look less like a path to inclusion and more like a permanent enclosure. Without robust, independent oversight, joint liability for investors, and a prioritization of humane, evidence-based supports over rigid behavior modification, the next generation of autistic children may pay the highest price of all.
This investigation was produced with support from the Education Writers Association Reporting Fellowship program.